

Janice E Graham

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5423608/publications.pdf>

Version: 2024-02-01

80
papers

3,232
citations

279487

23
h-index

155451

55
g-index

83
all docs

83
docs citations

83
times ranked

3637
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Stigma and blame related to COVID-19 pandemic: A case-study of editorial cartoons in Canada. <i>Social Science and Medicine</i> , 2022, 296, 114803. | 1.8 | 21 |
| 2 | Prebunking messaging to inoculate against COVID-19 vaccine misinformation: an effective strategy for public health. <i>Journal of Communication in Healthcare</i> , 2022, 15, 232-242. | 0.8 | 15 |
| 3 | The unintended consequences of COVID-19 vaccine policy: why mandates, passports and restrictions may cause more harm than good. <i>BMJ Global Health</i> , 2022, 7, e008684. | 2.0 | 122 |
| 4 | Deferring Risk: Limitations to the Evidence in Product Labels for Vaccine Use in Pregnancy. <i>Journal of Women's Health</i> , 2022, 31, 1103-1112. | 1.5 | 2 |
| 5 | â€œ <i>I donâ€™t think thereâ€™s a point for me to discuss it with my patientsâ€™</i> : exploring health care providersâ€™ views and behaviours regarding COVID-19 vaccination. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, . | 1.4 | 1 |
| 6 | Royal society of Canada COVID-19 report: Enhancing COVID-19 vaccine acceptance in Canada. <i>Facets</i> , 2021, 6, 1184-1246. | 1.1 | 25 |
| 7 | COVID-19 vaccine safety questions and answers for healthcare providers (CONSIDER). <i>Vaccine</i> , 2021, 39, 2504-2505. | 1.7 | 1 |
| 8 | Under consent: participation of people with HIV in an Ebola vaccine trial in Canada. <i>BMC Medical Ethics</i> , 2021, 22, 42. | 1.0 | 4 |
| 9 | Healthcare providersâ€™ interpretations of product labelling information developed through a consensus stakeholder approach. <i>Vaccine</i> , 2021, 39, 2652-2659. | 1.7 | 4 |
| 10 | Ethics check-up of public health immunization programs in Canada. <i>Canada Communicable Disease Report</i> , 2021, 47, 237-241. | 0.6 | 0 |
| 11 | From sandbox to pandemic: Agile reform of Canadian drug regulation. <i>Health Policy</i> , 2021, 125, 1115-1120. | 1.4 | 9 |
| 12 | Regulators, Pivotal Clinical Trials, and Drug Regulation in the Age of COVID-19. <i>International Journal of Health Services</i> , 2021, 51, 5-13. | 1.2 | 11 |
| 13 | Strengthening vaccination frameworks: Findings of a study on the legal foundations of National Immunization Technical Advisory Groups (NITAGs). <i>Vaccine</i> , 2020, 38, 840-846. | 1.7 | 0 |
| 14 | Governing off-label vaccine use: An environmental scan of the Global National Immunization Technical Advisory Group Network. <i>Vaccine</i> , 2020, 38, 1089-1095. | 1.7 | 5 |
| 15 | A public health timeline to prepare for COVID-19 vaccines in Canada. <i>Canadian Journal of Public Health</i> , 2020, 111, 945-952. | 1.1 | 11 |
| 16 | Immunization governance: Mandatory immunization in 28 Global NITAG Network countries. <i>Vaccine</i> , 2020, 38, 7258-7267. | 1.7 | 9 |
| 17 | Vaccination discourses among chiropractors, naturopaths and homeopaths: A qualitative content analysis of academic literature and Canadian organizational webpages. <i>PLoS ONE</i> , 2020, 15, e0236691. | 1.1 | 6 |
| 18 | Perinatal health care providersâ€™ approaches to recommending and providing pertussis vaccination in pregnancy: a qualitative study. <i>CMAJ Open</i> , 2020, 8, E377-E382. | 1.1 | 15 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | From discovery to delivery: public sector development of the <i>VSV-ZEBOV</i> Ebola vaccine. <i>Journal of Law and the Biosciences</i> , 2020, 7, lsz019. | 0.8 | 25 |
| 20 | Transparency too little, too late? Why and how Health Canada should make clinical data and regulatory decision-making open to scrutiny in the face of COVID-19. <i>Journal of Law and the Biosciences</i> , 2020, 7, lsa083. | 0.8 | 5 |
| 21 | Title is missing!. , 2020, 15, e0236691. | | 0 |
| 22 | Title is missing!. , 2020, 15, e0236691. | | 0 |
| 23 | Title is missing!. , 2020, 15, e0236691. | | 0 |
| 24 | Title is missing!. , 2020, 15, e0236691. | | 0 |
| 25 | Ebola vaccine innovation: a case study of pseudoscapes in global health. <i>Critical Public Health</i> , 2019, 29, 401-412. | 1.4 | 11 |
| 26 | How Do Postgenomic Innovations Emerge? Building Legitimacy by Proteomics Standards and Informing the Next-Generation Technology Policy. <i>OMICS A Journal of Integrative Biology</i> , 2019, 23, 406-415. | 1.0 | 0 |
| 27 | Developing product label information to support evidence-informed use of vaccines in pregnancy. <i>Vaccine</i> , 2019, 37, 7138-7146. | 1.7 | 9 |
| 28 | Is physician dismissal of vaccine refusers an acceptable practice in Canada? A 2018 overview. <i>Paediatrics and Child Health</i> , 2019, 24, 92-97. | 0.3 | 6 |
| 29 | Technologies of trust in epidemic response: openness, reflexivity and accountability during the 2014â€“2016 Ebola outbreak in West Africa. <i>BMJ Global Health</i> , 2019, 4, e001272. | 2.0 | 38 |
| 30 | North End Community Health Centre in Halifax, NS: Relationship-based care goes beyond collaborative care to address patient needs. <i>Canadian Family Physician</i> , 2019, 65, e344-e355. | 0.1 | 0 |
| 31 | Prepared for the "unexpected"? Lessons from the 2014â€“2016 Ebola epidemic in West Africa on integrating emergent theory designs into outbreak response. <i>BMJ Global Health</i> , 2018, 3, e000990. | 2.0 | 14 |
| 32 | Lueurs et leures de la sant  globale. <i>Anthropologie & D veloppement</i> , 2017, , 213-234. | 0.1 | 0 |
| 33 | Ambiguous Capture: Collaborative Capitalism and the Meningitis Vaccine Project. <i>Medical Anthropology: Cross Cultural Studies in Health and Illness</i> , 2016, 35, 419-432. | 0.6 | 14 |
| 34 | Just Evidence: Opening Health Knowledge to a Parliament of Evidence. , 2016, , 325-350. | | 0 |
| 35 | Knowledge Translation: Moving Proteomics Science to Innovation in Society. <i>OMICS A Journal of Integrative Biology</i> , 2016, 20, 352-361. | 1.0 | 3 |
| 36 | Exploring the post-genomic world: differing explanatory and manipulatory functions of post-genomic sciences. <i>New Genetics and Society</i> , 2016, 35, 49-68. | 0.7 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Understanding Vaccine Hesitancy in Canada: Results of a Consultation Study by the Canadian Immunization Research Network. PLoS ONE, 2016, 11, e0156118. | 1.1 | 121 |
| 38 | Regulating prescription drugs for patient safety: Does Bill C-17 go far enough?. Cmaj, 2014, 186, E287-E292. | 0.9 | 9 |
| 39 | Substitute consent practices in the face of uncertainty: a survey of Canadian researchers in aging. International Psychogeriatrics, 2013, 25, 1821-1830. | 0.6 | 6 |
| 40 | Faster Access to New Drugs: Fault Lines Between Health Canada's Regulatory Intent and Industry Innovation Practices. Ethics in Biology, Engineering & Medicine, 2013, 4, 231-239. | 0.1 | 4 |
| 41 | Risk, choice and the "girl vaccine"™: Unpacking human papillomavirus (HPV) immunisation. Health, Risk and Society, 2012, 14, 57-69. | 0.9 | 31 |
| 42 | Capacity for a global vaccine safety system: The perspective of national regulatory authorities. Vaccine, 2012, 30, 4953-4959. | 1.7 | 37 |
| 43 | Challenges to immunization: the experiences of homeless youth. BMC Public Health, 2012, 12, 338. | 1.2 | 15 |
| 44 | Are Canadians Providing Advance Directives about Health Care and Research Participation in the Event of Decisional Incapacity?. Canadian Journal of Psychiatry, 2011, 56, 209-218. | 0.9 | 19 |
| 45 | Is consent for research genuinely informed? Using decision aid tools to obtain informed consent in the global south. Journal of Global Ethics, 2011, 7, 349-359. | 0.1 | 9 |
| 46 | Comfort with proxy consent to research involving decisionally impaired older adults: do type of proxy and risk-benefit profile matter?. International Psychogeriatrics, 2011, 23, 1479-1488. | 0.6 | 12 |
| 47 | Global challenges of implementing human papillomavirus vaccines. International Journal for Equity in Health, 2011, 10, 27. | 1.5 | 48 |
| 48 | Standardization and Omics Science: Technical and Social Dimensions Are Inseparable and Demand Symmetrical Study. OMICS A Journal of Integrative Biology, 2010, 14, 327-332. | 1.0 | 24 |
| 49 | Assessment of factors associated with complete immunization coverage in children aged 12-23 months: a cross-sectional study in Nouna district, Burkina Faso. BMC International Health and Human Rights, 2009, 9, S10. | 2.5 | 86 |
| 50 | Genetically Modified Organisms as Public Goods: Plant Biotechnology Transfer in Colombia. Culture and Agriculture, 2009, 31, 26-38. | 0.2 | 3 |
| 51 | Multiple institutional rationalities in the regulation of health technologies: an ethnographic examination. Science and Public Policy, 2009, 36, 445-455. | 1.2 | 8 |
| 52 | Facilitating Regulation: The Dance of Statistical Significance and Clinical Meaningfulness in Standardizing Technologies for Dementia. BioSocieties, 2008, 3, 241-263. | 0.8 | 12 |
| 53 | Race as a variable in pharmacogenomics science: from empirical ethics to publication standards. Pharmacogenetics and Genomics, 2008, 18, 837-841. | 0.7 | 6 |
| 54 | Memorabilities: enduring relationships, memories and abilities in dementia. Ageing and Society, 2007, 27, 533-554. | 1.2 | 27 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Asymmetry in Scientific Method and Limits to Cross-Disciplinary Dialogue. <i>Journal of Investigative Medicine</i> , 2007, 55, 130-141. | 0.7 | 6 |
| 56 | The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial. <i>BMC Neurology</i> , 2007, 7, 26. | 0.8 | 90 |
| 57 | Mild Cognitive Impairment: Ethical Considerations for Nosological Flexibility in Human Kinds. <i>Philosophy, Psychiatry and Psychology</i> , 2006, 13, 31-43. | 0.2 | 26 |
| 58 | Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 119-133. | 0.9 | 28 |
| 59 | Reciprocal relations: The recognition and co-construction of caring with Alzheimer's disease. <i>Journal of Aging Studies</i> , 2006, 20, 335-349. | 0.7 | 43 |
| 60 | Anthropological contributions to the understanding of age-related cognitive impairment. <i>Lancet Neurology</i> , The, 2005, 4, 320-326. | 4.9 | 33 |
| 61 | Smart Regulation: Will the government's strategy work?. <i>Cmaj</i> , 2005, 173, 1469-1470. | 0.9 | 15 |
| 62 | Multigenic Control of Drug Response and Regulatory Decision-Making in Pharmacogenomics: The Need for an Upper-Bound Estimate of Genetic Contributions. <i>Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics</i> , 2005, 3, 53-71. | 0.3 | 26 |
| 63 | Techniques for knowledge discovery in existing biomedical databases Estimation of individual aging effects in cognition in relation to dementia. <i>Journal of Clinical Epidemiology</i> , 2003, 56, 116-123. | 2.4 | 10 |
| 64 | Actor-Network Theory: a tool to support ethical analysis of commercial genetic testing. <i>New Genetics and Society</i> , 2003, 22, 271-296. | 0.7 | 85 |
| 65 | Five-Year Follow-up of Cognitive Impairment With No Dementia. <i>Archives of Neurology</i> , 2003, 60, 577. | 4.9 | 190 |
| 66 | Patterns and Health Effects of Caring for People With Dementia: The Impact of Changing Cognitive and Residential Status. <i>Gerontologist</i> , The, 2002, 42, 643-652. | 2.3 | 37 |
| 67 | Frailty, fitness and late-life mortality in relation to chronological and biological age. <i>BMC Geriatrics</i> , 2002, 2, 1. | 1.1 | 560 |
| 68 | Harbinger of Hope or Commodity Fetishism: "Re-cognizing" Dementia in an Age of Therapeutic Agents. <i>International Psychogeriatrics</i> , 2001, 13, 131-134. | 0.6 | 14 |
| 69 | Qualitative Analysis of the Clinician Interview-Based Impression of Change (Plus): Methodological Issues and Implications for Clinical Research. <i>International Psychogeriatrics</i> , 2000, 12, 403-413. | 0.6 | 36 |
| 70 | Prevalence of Cognitive Impairment and Dementia as Defined by Neuropsychological Test Performance. <i>Neuroepidemiology</i> , 2000, 19, 121-129. | 1.1 | 14 |
| 71 | The Rate of Decline in Function in Alzheimer's Disease and Other Dementias. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 1999, 54, M65-M69. | 1.7 | 39 |
| 72 | Dynamics of Cognitive Aging: Distinguishing Functional Age and Disease from Chronologic Age in a Population. <i>American Journal of Epidemiology</i> , 1999, 150, 1045-1054. | 1.6 | 30 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Factors Associated with Inconsistent Diagnosis of Dementia Between Physicians and Neuropsychologists. <i>Journal of the American Geriatrics Society</i> , 1999, 47, 1294-1299. | 1.3 | 22 |
| 74 | Modeling Decline in Alzheimer's Disease. <i>International Psychogeriatrics</i> , 1999, 11, 211-213. | 0.6 | 2 |
| 75 | Vector Diagnostics in Dementia Derived from Bayes' Theorem. <i>American Journal of Epidemiology</i> , 1997, 146, 665-671. | 1.6 | 10 |
| 76 | Prevalence and severity of cognitive impairment with and without dementia in an elderly population. <i>Lancet</i> , The, 1997, 349, 1793-1796. | 6.3 | 893 |
| 77 | Symptoms and Signs in Dementia Synergy and Antagonism. <i>Dementia and Geriatric Cognitive Disorders</i> , 1996, 7, 331-335. | 0.7 | 12 |
| 78 | Standardization of the Diagnosis of Dementia in the Canadian Study of Health and Aging. <i>Neuroepidemiology</i> , 1996, 15, 246-256. | 1.1 | 126 |
| 79 | An Algorithmic Approach to the Differential Diagnosis of Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 1996, 7, 324-330. | 0.7 | 5 |
| 80 | Rendre "évident": une approche symbolique de la réglementation des produits thérapeutiques. <i>Sociologie Et Sociétés</i> , 0, 42, 153-180. | 0.1 | 5 |